288 related articles for article (PubMed ID: 31290039)
21. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
Walker GJ; Harrison JW; Heap GA; Voskuil MD; Andersen V; Anderson CA; Ananthakrishnan AN; Barrett JC; Beaugerie L; Bewshea CM; Cole AT; Cummings FR; Daly MJ; Ellul P; Fedorak RN; Festen EAM; Florin TH; Gaya DR; Halfvarson J; Hart AL; Heerasing NM; Hendy P; Irving PM; Jones SE; Koskela J; Lindsay JO; Mansfield JC; McGovern D; Parkes M; Pollok RCG; Ramakrishnan S; Rampton DS; Rivas MA; Russell RK; Schultz M; Sebastian S; Seksik P; Singh A; So K; Sokol H; Subramaniam K; Todd A; Annese V; Weersma RK; Xavier R; Ward R; Weedon MN; Goodhand JR; Kennedy NA; Ahmad T;
JAMA; 2019 Feb; 321(8):773-785. PubMed ID: 30806694
[TBL] [Abstract][Full Text] [Related]
22. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
23. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Chisick L; Oleschuk C; Bernstein CN
Can J Gastroenterol; 2013 Jan; 27(1):39-43. PubMed ID: 23378982
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
Akiyama S; Matsuoka K; Fukuda K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Motobayashi M; Suzuki K; Takenaka K; Fujii T; Saito E; Nagahori M; Ohtsuka K; Mochizuki M; Watanabe M; Hashiguchi M; Kanai T
J Gastroenterol Hepatol; 2019 Oct; 34(10):1751-1757. PubMed ID: 31045285
[TBL] [Abstract][Full Text] [Related]
25. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
26. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
[TBL] [Abstract][Full Text] [Related]
27. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Gutiérrez-Valencia M; Leache L; Saiz LC; Beloqui JJ; Barajas M; Vicuña M; Erviti J
J Clin Gastroenterol; 2023 Aug; 57(7):671-685. PubMed ID: 36322453
[TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
29. Influence of
Kojima Y; Hirotsu Y; Omata W; Sugimori M; Takaoka S; Ashizawa H; Nakagomi K; Yoshimura D; Hosoda K; Suzuki Y; Mochizuki H; Omata M
World J Gastroenterol; 2018 Jan; 24(4):511-518. PubMed ID: 29398872
[TBL] [Abstract][Full Text] [Related]
30. Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.
Root A; Johnson R; McGee A; Lee HJ; Yang S; Voora D
Pharmacogenomics; 2020 Apr; 21(6):411-418. PubMed ID: 32308127
[No Abstract] [Full Text] [Related]
31. Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.
Coelho T; Andreoletti G; Ashton JJ; Batra A; Afzal NA; Gao Y; Williams AP; Beattie RM; Ennis S
Sci Rep; 2016 Oct; 6():34658. PubMed ID: 27703193
[TBL] [Abstract][Full Text] [Related]
32. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
Dubinsky MC
Clin Gastroenterol Hepatol; 2004 Sep; 2(9):731-43. PubMed ID: 15354273
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for gastrointestinal adverse events related to thiopurine therapy.
Zudeh G; Franca R; Stocco G; Decorti G
World J Gastroenterol; 2021 Oct; 27(38):6348-6356. PubMed ID: 34720526
[TBL] [Abstract][Full Text] [Related]
34. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
36. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
Cuffari C; Dassopoulos T; Turnbough L; Thompson RE; Bayless TM
Clin Gastroenterol Hepatol; 2004 May; 2(5):410-7. PubMed ID: 15118980
[TBL] [Abstract][Full Text] [Related]
37. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Díaz-Villamarín X; Fernández-Varón E; Rojas Romero MC; Callejas-Rubio JL; Cabeza-Barrera J; Rodríguez-Nogales A; Gálvez J; Morón R
Biomed Pharmacother; 2023 Dec; 168():115706. PubMed ID: 37857254
[TBL] [Abstract][Full Text] [Related]
38. An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients.
Chen S; Tan WZ; Sutiman N; Lim C; Lee SS; Leong WF; Tjai M; Wang C; Kong CSC; Chuah SW; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Ling KL; Chowbay B
Pharmacogenomics J; 2020 Jun; 20(3):505-515. PubMed ID: 31813937
[TBL] [Abstract][Full Text] [Related]
39. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
40. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
Desai D; Jena A; Sharma V; Hibi T
Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
